The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMPN 2026 | Insights into the current role of ropeginterferon in the ET treatment landscape
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the approval of ropeginterferon for essential thrombocythemia (ET), highlighting its broad label for use in patients with ET who need therapy, including frontline or second-line options. Dr Masarova advises clinicians to consider ropeginterferon for patients who have failed frontline therapies and for young patients or those seeking more than just count control. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
